BACKGROUND: The heterogeneous histological features of melanoma may often overlap with melanocytic nevi. For this reason, pathologists have sought after immunohistochemistry to assist with difficult cases. Recently, Wilms' tumor 1 protein (WT1) has been suggested to differentiate between melanoma and melanocytic nevi. OBJECTIVE: Our objective was to determine whether immunohistochemistry analysis of WT1 expression is a reliable tool in differentiating cutaneous melanoma from melanocytic nevi. METHODS: Forty-five melanoma and 43 melanocytic nevi were immunostained with anti-WT1 monoclonal antibody (clone 6F-H2). RESULTS: Forty of the 45 cutaneous melanoma (89%) and 22 of the 43 melanocytic nevi (51%) stained (> 10% cells) for WT1. The highest sensitivity for WT1 was expressed by nodular melanoma (19/20), superficial spreading melanoma (8/10) and Spitz nevi (9/11). At the threshold of above 75% WT1-stained cells, the specificity for melanoma was 95% but the sensitivity was only 31%. At the threshold of 10%, the sensitivity increased to 89% but the specificity decreased to only 49%. Finally, at the threshold of 25% and 50%, the sensitivity and specificity were 71%, 61% and 64%, 77%, respectively. CONCLUSIONS: Our data suggest that melanoma is associated with increased WT1 expression. However, as a single immunostaining marker, WT1 is not sufficient for distinguishing melanoma from melanocytic nevi. 2009 John Wiley & Sons A/S.
BACKGROUND: The heterogeneous histological features of melanoma may often overlap with melanocytic nevi. For this reason, pathologists have sought after immunohistochemistry to assist with difficult cases. Recently, Wilms' tumor 1 protein (WT1) has been suggested to differentiate between melanoma and melanocytic nevi. OBJECTIVE: Our objective was to determine whether immunohistochemistry analysis of WT1 expression is a reliable tool in differentiating cutaneous melanoma from melanocytic nevi. METHODS: Forty-five melanoma and 43 melanocytic nevi were immunostained with anti-WT1 monoclonal antibody (clone 6F-H2). RESULTS: Forty of the 45 cutaneous melanoma (89%) and 22 of the 43 melanocytic nevi (51%) stained (> 10% cells) for WT1. The highest sensitivity for WT1 was expressed by nodular melanoma (19/20), superficial spreading melanoma (8/10) and Spitz nevi (9/11). At the threshold of above 75% WT1-stained cells, the specificity for melanoma was 95% but the sensitivity was only 31%. At the threshold of 10%, the sensitivity increased to 89% but the specificity decreased to only 49%. Finally, at the threshold of 25% and 50%, the sensitivity and specificity were 71%, 61% and 64%, 77%, respectively. CONCLUSIONS: Our data suggest that melanoma is associated with increased WT1 expression. However, as a single immunostaining marker, WT1 is not sufficient for distinguishing melanoma from melanocytic nevi. 2009 John Wiley & Sons A/S.
Authors: H Tamaki; H Ogawa; K Ohyashiki; J H Ohyashiki; H Iwama; K Inoue; T Soma; Y Oka; T Tatekawa; Y Oji; A Tsuboi; E H Kim; M Kawakami; K Fuchigami; M Tomonaga; K Toyama; K Aozasa; T Kishimoto; H Sugiyama Journal: Leukemia Date: 1999-03 Impact factor: 11.528
Authors: U Rodeck; A Bossler; C Kari; C W Humphreys; T Györfi; J Maurer; E Thiel; H D Menssen Journal: Int J Cancer Date: 1994-10-01 Impact factor: 7.396
Authors: L Pilloni; P Bianco; E Difelice; S Cabras; M E Castellanos; L Atzori; C Ferreli; P Mulas; S Nemolato; G Faa Journal: Eur J Histochem Date: 2011-06-07 Impact factor: 3.188
Authors: Karli Rosner; Darius R Mehregan; Evangelia Kirou; Judith Abrams; Seongho Kim; Michelle Campbell; Jillian Frieder; Kelsey Lawrence; Brittany Haynes; Malathy P V Shekhar Journal: J Skin Cancer Date: 2014-05-06